Conference Coverage

VIDEO: Consider comorbidities when preparing patients for systemic psoriasis therapy


 

EXPERT ANALYSIS AT SDEF LAS VEGAS DERMATOLOGY SEMINAR

– Clinicians should consider the increased risk for multiple comorbidities in their patients with psoriasis, Joel M. Gelfand, MD, said in a video interview at the Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

“These are patients who should undergo the type of age-appropriate screening that any patient should have,” including checks for blood pressure and diabetes, said Dr. Gelfand, professor of dermatology and epidemiology at the University of Pennsylvania, Philadelphia.

In terms of preparing for systemic psoriasis therapy, “there are lots of things we can do to lower the risk of having bad outcomes,” including age-appropriate cancer screening such as colonoscopy and mammography, he added. Vaccination is also an important strategy to help reduce the risk of potential side effects related to immunosuppression, he noted.

Dr. Gelfand disclosed relationships with multiple companies including AbbVie, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi, and Valeant.

SDEF and this news organization are owned by the same parent company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

PsA bone loss measurement: A surrogate for radiographic progression?
MDedge Dermatology
Close monitoring of psoriasis patients can delay PsA onset
MDedge Dermatology
Include quality of life measures in evaluating treatment success of psoriasis
MDedge Dermatology
FDA: Etanercept first biologic approved for pediatric psoriasis
MDedge Dermatology
What good are biosimilars if patients won’t use them?
MDedge Dermatology
Optimize anti–TNF-alpha therapy for psoriasis
MDedge Dermatology
Study offers reassuring data on certolizumab use in pregnancy
MDedge Dermatology
Biologic-naive psoriasis patients get biggest boost with treatment
MDedge Dermatology
VIDEO: IL-23 inhibitors on the upswing
MDedge Dermatology
VIDEO: Biosimilars show promise and progress
MDedge Dermatology